AIM ImmunoTech Accelerates Toward Potential Pivotal Pancreatic Cancer Program as Ampligen Continues to Advance Through Key Clinical Milestones

Stock Information for AIM ImmunoTech Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About AIM ImmunoTech Inc.

AIM ImmunoTech Ahead of Schedule on 'Last Dose' DURIPANC Critical Clinical Inflection Point
AIM ImmunoTech Announces Release of New CEO Corner Segment Highlighting Growing Momentum Across Pancreatic Cancer Program
AIM ImmunoTech to Present in the Webull Corporate Connect Webinar Series
AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer
AIM ImmunoTech Regains NYSE American Compliance, Company Resolves Stockholder Equity Deficiency
AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market under NYSE American Rules
AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca's Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
AIM ImmunoTech Releases Virtual Investor 'What This Means' Video Segment Discussing Ampligen's Potential in Ebola Virus Disease Preparedness

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.